25 Jul 2025
We are thrilled to announce that EpiCure, a startup emerging from Cohort 5 of the LMU Innovation Incubator, has been awarded the prestigious m⁴ Award by the Free State of Bavaria.
EpiCure is pioneering next-generation epigenetic cancer therapies for hematologic malignancies, aiming for significantly improved efficacy and a 100-fold reduction in toxicity compared to conventional treatments. With over 750,000 patients affected globally each year, the team is addressing a pressing need for safer and more effective therapeutic options.
Endowed with €500,000, the m⁴ Award supports academic research projects with strong translational potential. The funding will drive key preclinical studies, laying the groundwork for first-in-human trials and an upcoming spin-off from LMU.
This award highlights not only the scientific strength of EpiCure’s approach but also the broader mission of the LMU Innovation Incubator: to help transform high-impact research into real-world innovation.
Congratulations to the EpiCure team on this remarkable achievement! we look forward to following your journey and the difference you will make in the field of biotech.